MAPT and Alzheimer disease: More recently, several guidelines indicate the quantification of Aβ42, total tau (t-tau) and tau phosphorylated at threonine 181 (p-tau) in blood samples and in the cerebrospinal fluid (CSF) as indicators for AD clinical diagnosis [3,4,5,6,7].